Investigational drug · Phase 2
ALN-PNP
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Healthy Volunteers.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "ALN-PNP"
First trial start
2022
Dec 27, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ALN-PNP", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Healthy Volunteers
Approved drugs for the same conditions: Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "ALN-PNP" as an intervention, largest first.
- A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLDPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07527910 · 204 participants (planned) · Start May 22, 2026 · Primary completion Mar 15, 2030
Drug: ALN-PNP; Tirzepatide and 1 more · For: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Sites: Tucson, Arizona; Coronado, California; Pasadena, California · 10 sites in all
- A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05648214 · 172 participants (planned) · Start Dec 27, 2022 · Primary completion Aug 10, 2027
Drug: ALN-PNP; Placebo (PB) · For: Healthy Volunteers; Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Sites: Glendale, California; Los Angeles, California; Miami, Florida · 6 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06024408 · 9 participants · Start May 21, 2024 · Primary completion Jul 7, 2025
Drug: ALN-PNP; Placebo · For: Nonalcoholic Fatty Liver Disease (NAFLD); Nonalcoholic Steatohepatitis (NASH); Genetic Risk Factor
Sites: Cheongju-si, South Korea; Seongnam-si, South Korea; Seoul, South Korea · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.